Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic startThe Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.{}

The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.https://www.cnbc.com/2026/02/11/novo-nordisk-faces-defining-year-in-the-obesity-drug-market.html